검색어: tbatti (몰타어 - 영어)

tirkadi u tbatti
85% (37%)

sklerożi multipla li tirkadi u tbatti
relapsing- remitting multiple sclerosis

sklerożi multipla li tirkadi u tbatti:
in this leaflet:

sklerożi multipla li tirkadi-tbatti (rr-ms)
relapsing-remitting multiple sclerosis (rr-ms)

ladarba l-irr ħafifa jew moderata tbatti, kompli l-infużjoni.
once the mild or moderate irr subsides, continue the infusion.

bħallkarozza tiegħek, jekk ma tużax il-lingwa regolarment din tbatti u tissaddad.
‘they will be pleased and impressed at your ability, even when this is still quite limited.’

tecfidera jintuża għal kura ta’ sklerożi multipla (ms) li tirkadi u tbatti.
tecfidera is used to treat relapsing-remitting multiple sclerosis (ms).

sostituzzjoni xierqa tal-ilma u/jew tal-elettroliti għandha tikompla sakemm l-akwaresi tbatti.
appropriate replacement of water and/or electrolytes must continue until aquaresis abates.

għal sklerożi multipla li tirkadi u tbatti l-effikaċja tat-terapija ġiet murija għall-ewwel sentejn.
for relapsing-remitting ms, efficacy has been demonstrated for therapy for the first two years.

pazjenti bi sklerożi multipla li tirkadi u tbatti b’żewġ episodji ta’ rkadar jew iktar fl-aħħar sentejn.
patients with relapsing remitting multiple sclerosis and two or more relapses within the last two years.

madanakollu, it-tul tal-istaġun turistiku ħafna drabi huwa wisq limitat biex joffri alternattiva reali għal attività ekonomika li qed tbatti.
however, the length of the tourist season is often too limited to offer a real alternative to declining economic activity.

jekk ikollok sturdament jew kwalunkwe sintomi oħra li jaffettwaw il-ħila tiegħek li tikkonċentra u tirreaġixxi, issuqx u tħaddimx magni qabel ir-reazzjoni tbatti.
if you experience dizziness or any other symptoms affecting your ability to concentrate and react, do not drive or use machines until the reaction subsides.

hemm tagħrif tal- follow-up taħt kundizzjonijiet kliniċi kontrollati għal pazjenti li għandhom sklerożi multipla li tirkadi u tbatti sa 5 snin u għal pazjenti li għandhom sklerożi multipla progressiva sekondarja sa 3 snin.
there are follow-up data under controlled clinical conditions for patients with relapsing-remitting multiple sclerosis for up to 5 years and for patients with secondary progressive multiple sclerosis for up to 3 years.

tysabri huwa indikat bħala monoterapija li timmodifika l- marda fi sklerożi multipla attiva ħafna li tirkada u tbatti għall- ġruppi ta ’ pazjenti li ġejjin:
tysabri is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following patient groups:

persuni b’ ms li tirkadi u tbatti jkollhom attakki kull tant żmien jew rikaduti li matulhom is- sintomi jmorru għall- agħar b’ mod notevoli.
people with relapsing-remitting ms have occasional attacks or relapses during which symptoms become noticeably worse.

għall-pazjenti bi sklerożi multipla li tirkadi u tbatti hemm tagħrif meħud wara l-bidu tal-kura taħt kundizzjonijiet kliniċi kkontrollati sa 5 snin u għal pazjenti bi sklerożi multipla progressiva sekondarja hemm tagħrif sa 3 snin.
there are follow-up data under controlled clinical conditions for patients with relapsing-remitting ms for up to 5 years and for patients with secondary progressive ms for up to 3 years.